摘要
目的:探讨扶正解毒中药复方配合新辅助化疗治疗乳腺癌的临床意义。方法:将临床分期为Ⅱ～Ⅲ期乳腺癌的病人分为治疗组和化疗后对照组,治疗组用复康灵+CTF方案化疗3个周期,对照组CTF方案化疗3个周期,疗程结束后观察近期疗效并采用免疫组织化学方法检测新辅助化疗前后肿瘤组织中P-gp及GST-π的表达,进行组间比较及相关性分析。结果:近期疗效治疗组的完全缓解4例,缓解率为12.1%,总缓解率为72.7%;对照组无完全缓解例数,总缓解率为45%,2组间比较差异有统计学意义;治疗组新辅助化疗前后P-gp和GST-π阳性率均增高,前者差异有统计学意义;2组化疗后治疗组P-gp阳性率为12.1%,对照组P-gp阳性率为40.0%,2组比较差异有统计学意义;治疗组GST-π阳性率为36.4%,对照组GST-π阳性率为55.0%2,组比较无统计学意义。结论:乳腺癌新辅助化疗可使肿瘤缩小,降低临床分期,有助于手术治疗及术式的选择,而扶正解毒中药复方复康灵配合新辅助化疗治疗乳腺癌可以逆转多药耐药的部分基因表达,从而提高化疗疗效,起减毒增效作用。
Objective： To discuss clinical significance of Chinese herbal compound of support vital Qi and remove toxin cooperate with neoadjuvant chemotherapy in treating breast cancer.Methods：Patients with phase Ⅱ～Ⅲ breast cancer were divided into treatment and control group.The treatment group were treated with FuKangLing and CTF plan chemotherapy 3 periods,the control were only treated with CTF plan chemotherapy 3 periods.Both group would be observed effect and tested the expression of P-gp and GST-π in tumor tissue with immunohistochemical method.Result： The complete remission rate of treatment group was 12.1%,total rate 72.7%,no one was eased in control group,total rate 45%,and the difference between two groups had statistically significance.The positive rate of P-gp and GST-πin treatment group both increased,and the difference of former had statistically significance.The positive rate of P-gp was 12.1%in treatment,40.0% in control group,the difference had statistically significance.The positive rate of GST-πwas 36.4%in treatment,55.0% in control group.Conclusion：Neoadjuvant chemotherapy in treating breast cancer could reduce the tumor,decrease clinical phase and help to operation choose and Chinese herb compound FuKangLing cooperate with neoadjuvant chemotherapy in treating breast cancer could reverse multi-drug resistance gene expression,thereby enhancing the efficacy of chemotherapy,reducing toxin.
出处
《甘肃中医》
2010年第12期31-33,共3页
Gansu Journal of Traditional Chinese Medicine
关键词
扶正解毒
乳腺癌
新辅助化疗
多药耐药
support vital Qi and remove toxin
breast cancer
neoadjuvant chemotherapy
multi-drug resistance
